Gene Therapy Company AavantiBio Launches with $107 Million Series A Financing from Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management and Sarepta Therapeutics


Excerpt from the Press Release: CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) — A premier syndicate of life sciences investors including Perceptive Advisors, Bain Capital Life Sciences (“Bain Capital”), and RA Capital Management (“RA Capital”) (collectively the “Investor Group”) together with Sarepta Therapeutics, Inc. (“Sarepta”) (NASDAQ: SRPT), a leader in precision genetic medicine for rare…

Read More

Nobel Prize in Chemistry


Excerpt from the Press Release: ZUG, Switzerland and CAMBRIDGE, Mass., Oct. 07, 2020 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), today announced Professor Emmanuelle Charpentier, CRISPR Therapeutics’ co-founder, has been awarded the 2020 Nobel Prize in Chemistry for her groundbreaking work on the CRISPR/Cas9 system. Professor Charpentier co-founded CRISPR Therapeutics together with Rodger Novak and Shaun…

Read More

Celebrating Impact of BioScience Sector in PEI During Global Biotech Week


Excerpt from the Press Release: Charlottetown, PE – From COVID-19 vaccines and diagnostics, to understanding climate change, producing animal health products, and feeding the world sustainably, life sciences continues to be an area of high-demand in solving the challenges facing our society. Dedicated to celebrating science, innovation and solutions, this year’s Global Biotech Week (GBW)…

Read More

We Had An Outstanding Time Exhibiting, Presenting and Networking at the Virtual SCDM 2020 Meeting


On September 13th we began our virtual exhibition at the SCDM 2020 meeting. What a fantastic event this year! Despite having to go virtual, the SCDM meeting organizers and AV partner were able to produce an outstanding meeting for the attendees and vendors with plenty of opportunities to network, present and of course, learn! Congratulations…

Read More

Spero Therapeutics Announces Positive Topline Results from its Phase 3 ADAPT-PO Clinical Trial of Oral Tebipenem HBr in Complicated Urinary Tract Infection and Acute Pyelonephritis


Excerpt from the Press Release: CAMBRIDGE, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet medical need areas involving multidrug-resistant (MDR) bacterial infections and rare diseases, today announced positive topline results from ADAPT-PO, the pivotal Phase 3 clinical…

Read More

Health and life sciences companies focused on mental health and wellness invited to pitch at second Health Challenge Event


Excerpt from the announcement: Health and life sciences companies in Atlantic Canada are being invited to present their innovative solutions for improving mental health and wellness of Nova Scotians during the second Health Challenge Pitch Event. Participants will vie for a $100,000 prize and an opportunity to launch their product in collaboration with Nova Scotia…

Read More

Ask Us Anything in Clinical Research – Our Ongoing Virtual Networking Series


With many of our industry meetings either canceled or going virtual, we were really missing out on the casual networking we used to do at this events. If we were missing, it we thought many of you were too. So we decided to create an ongoing virtual networking series called Ask Us Anything In Clinical…

Read More

Meet with Christopher Kata virtually during “SCDM 2020” September 13th to 16th!


Christopher Kata and the TrialStat team are exhibiting virtually at this years SCDM meeting on September 13th through the 16th. If you’re attending be sure to to reach out to Christopher to schedule a one on meeting. You can also catch our video Pitch Presentation, and Product Showcase, or visit our Virtual Booth to learn…

Read More

Oncorus Initiates First-in-Human Phase 1 Study of ONCR-177 for the Treatment of Adult Subjects with Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors


Excerpt from the Press Release “CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oncorus, Inc., a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that it has initiated a Phase 1 study of its lead product candidate, ONCR-177, an intratumorally administered oncolytic Herpes Simplex Virus (oHSV) viral immunotherapy being developed for multiple solid tumor…

Read More

Medicine By Design – New Ideas Awards 2020


The 2020 Medicine by Design New Ideas Awards will focus on seeding new ideas that have strong potential to advance regenerative medicine research. Each funded project will receive up to $100,000 per year for a two-year period from July 1, 2020, to June 30, 2022. Proposed projects must align with at least one of the…

Read More